MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,551K
EPS
$5.17
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research And Development
2,212
1,370
2,377*
2,157
General And Administrative
1,468
1,379
891*
1,135
Total operating expenses
3,680
2,749
3,267
3,292
Operating loss
-3,680
-
-3,267*
-3,292
Financial expenses
-129
-16
-2*
-30
Loss before income tax
-3,551
-2,733
-3,265*
-3,262
Income tax
-
-
-1*
0
Net loss
-3,551
-2,733
-3,264
-3,262
Basic EPS
5.17
0.85
-2.455
2.88
Diluted EPS
5.17
0.85
-2.455
2.88
Basic Average Shares
687,353
3,230,378
1,329,515*
1,132,658
Diluted Average Shares
687,353
3,230,378
1,329,515*
1,132,658
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$3,551K
(-41.87%↓ Y/Y)
Loss before income
tax
-$3,551K
(-42.04%↓ Y/Y)
Financial expenses
-$129K
(-159.72%↓ Y/Y)
Operating loss
-$3,680K
(-61.12%↓ Y/Y)
Total operating
expenses
$3,680K
(61.12%↑ Y/Y)
Research And Development
$2,212K
(117.29%↑ Y/Y)
General And
Administrative
$1,468K
(15.96%↑ Y/Y)
Buy us a coffee
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)